239 related articles for article (PubMed ID: 34743314)
1. Efmoroctocog Alfa: A Review in Haemophilia A.
Frampton JE
Drugs; 2021 Nov; 81(17):2035-2046. PubMed ID: 34743314
[TBL] [Abstract][Full Text] [Related]
2. Efmoroctocog Alfa: A Review in Haemophilia A.
Frampton JE
Drugs; 2016 Sep; 76(13):1281-1291. PubMed ID: 27487799
[TBL] [Abstract][Full Text] [Related]
3. Multicentre pharmacokinetic evaluation of rFVIII-Fc (efmoroctocog alfa) in a real life and comparison with non-extended half-life FVIII concentrates.
Pouplard C; Sattler L; Ryman A; Eschwege V; De Maistre E; Flaujac C; Szymezak J; Grand F; Repesse Y; Galinat H; Donnard M; Ternisien C; Iorio A; Chelle P; Jeanpierre E;
Haemophilia; 2020 Mar; 26(2):282-289. PubMed ID: 32107819
[TBL] [Abstract][Full Text] [Related]
4. Real-world evidence on efmoroctocog alfa in patients with haemophilia A: A systematic literature review of treatment experience in Europe.
Blatný J; Nielsen EM; Reitzel SB; McMillan AC; Danø A; Bystrická L; Kragh N; Klamroth R
Haemophilia; 2023 Jul; 29(4):963-974. PubMed ID: 37243934
[TBL] [Abstract][Full Text] [Related]
5. Optimising prophylaxis outcomes and costs in haemophilia patients switching to recombinant FVIII-Fc: a single-centre real-world experience.
Tagliaferri A; Matichecchia A; Rivolta GF; Riccardi F; Quintavalle G; Benegiamo A; Rossi R; Coppola A
Blood Transfus; 2020 Sep; 18(5):374-385. PubMed ID: 31855153
[TBL] [Abstract][Full Text] [Related]
6. A Retrospective Observational Study of Rurioctocog Alfa Pegol in Clinical Practice in the United States.
Aledort L; Milligan S; Watt M; Booth J
J Manag Care Spec Pharm; 2020 Apr; 26(4):492-503. PubMed ID: 32223610
[TBL] [Abstract][Full Text] [Related]
7. Matching-Adjusted Indirect Comparison of Efficacy and Consumption of rVIII-SingleChain Versus Two Recombinant FVIII Products Used for Prophylactic Treatment of Adults/Adolescents with Severe Haemophilia A.
Bonanad S; Núñez R; Poveda JL; Kurnik K; Goldmann G; Andreozzi V; Vandewalle B; Santos S
Adv Ther; 2021 Sep; 38(9):4872-4884. PubMed ID: 34368918
[TBL] [Abstract][Full Text] [Related]
8. Status of Recombinant Factor VIII Concentrate Treatment for Hemophilia a in Italy: Characteristics and Clinical Benefits.
Schiavoni M; Napolitano M; Giuffrida G; Coluccia A; Siragusa S; Calafiore V; Lassandro G; Giordano P
Front Med (Lausanne); 2019; 6():261. PubMed ID: 31850352
[TBL] [Abstract][Full Text] [Related]
9. Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients.
Powell JS; Josephson NC; Quon D; Ragni MV; Cheng G; Li E; Jiang H; Li L; Dumont JA; Goyal J; Zhang X; Sommer J; McCue J; Barbetti M; Luk A; Pierce GF
Blood; 2012 Mar; 119(13):3031-7. PubMed ID: 22223821
[TBL] [Abstract][Full Text] [Related]
10. Switching from standard to extended half-life FVIII prophylaxis in haemophilia A: Comparison of factor product use, bleed rates and pharmacokinetics.
Nummi V; Lehtinen AE; Iorio A; Szanto T; Lassila R
Haemophilia; 2022 Nov; 28(6):e237-e244. PubMed ID: 35939628
[TBL] [Abstract][Full Text] [Related]
11. The Australian experience with switching to extended half-life factor VIII and IX concentrates: On behalf of the Australian Haemophilia Centre Directors' Organisation.
Brennan Y; Parikh S; McRae S; Tran H
Haemophilia; 2020 May; 26(3):529-535. PubMed ID: 32243027
[TBL] [Abstract][Full Text] [Related]
12. Clinical efficacy of simoctocog alfa versus extended half-life recombinant FVIII concentrates in hemophilia A patients undergoing personalized prophylaxis using a matching-adjusted indirect comparison method.
Kessler CM; Corrales-Medina FF; Mannucci PM; Jiménez-Yuste V; Tarantino MD
Eur J Haematol; 2023 Nov; 111(5):757-767. PubMed ID: 37587687
[TBL] [Abstract][Full Text] [Related]
13. Clinical outcomes of low-dose pharmacokinetic-guided extended half-life versus low-dose standard half-life factor VIII concentrate prophylaxis in haemophilia A patients.
Rakmanotham A; Moonla C; Sosothikul D
Haemophilia; 2023 Jan; 29(1):156-164. PubMed ID: 36409282
[TBL] [Abstract][Full Text] [Related]
14. Recombinant factor VIII Fc for the treatment of haemophilia A.
Hermans C; Mancuso ME; Nolan B; Pasi KJ
Eur J Haematol; 2021 Jun; 106(6):745-761. PubMed ID: 33650192
[TBL] [Abstract][Full Text] [Related]
15. [Switching toward the use of recombinant factor VIII Fc fusion protein Study among 30 patients with severe hemophilia A].
Sattler L; Raissi A; Fornoff D; Gérout AC; Feugeas O; Grunebaum L; Desprez D
Ann Biol Clin (Paris); 2020 Feb; 78(1):35-46. PubMed ID: 32108578
[TBL] [Abstract][Full Text] [Related]
16. Budget impact analysis of the use of extended half-life recombinant factor VIII (efmoroctocog alfa) for the treatment of congenital haemophilia a: the Italian National Health System perspective.
Lorenzoni V; Triulzi I; Turchetti G
BMC Health Serv Res; 2018 Aug; 18(1):596. PubMed ID: 30071878
[TBL] [Abstract][Full Text] [Related]
17. Recombinant factor VIII Fc fusion protein: extended-interval dosing maintains low bleeding rates and correlates with von Willebrand factor levels.
Shapiro AD; Ragni MV; Kulkarni R; Oldenberg J; Srivastava A; Quon DV; Pasi KJ; Hanabusa H; Pabinger I; Mahlangu J; Fogarty P; Lillicrap D; Kulke S; Potts J; Neelakantan S; Nestorov I; Li S; Dumont JA; Jiang H; Brennan A; Pierce GF
J Thromb Haemost; 2014 Nov; 12(11):1788-800. PubMed ID: 25196897
[TBL] [Abstract][Full Text] [Related]
18. Haemophilia A patients' medication adherence to prophylaxis with efmoroctocog alfa.
Pitance V; Désage S; Lienhart A; Meunier S; Chamouard V
Haemophilia; 2021 May; 27(3):e368-e375. PubMed ID: 33780111
[TBL] [Abstract][Full Text] [Related]
19. Comparative analysis of the pivotal studies of extended half-life recombinant FVIII products for treatment of haemophilia A.
Mannucci PM; Cortesi PA; Di Minno MND; Sanò M; Mantovani LG; Di Minno G
Haemophilia; 2021 Jul; 27(4):e422-e433. PubMed ID: 33955638
[TBL] [Abstract][Full Text] [Related]
20. Predicting the outcomes of using longer-acting prophylactic factor VIII to treat people with severe hemophilia A: a hypothetical decision analysis.
Miners AH; Krishnan S; Pasi KJ
J Thromb Haemost; 2016 Nov; 14(11):2141-2147. PubMed ID: 27510890
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
